The company has substantially advanced its progress of an novel therapy for ATTR-CM, utilizing the compound. Initial patient results reveals promising improvements for individuals affected by a severe disease. The focus https://attruby751582.look4blog.com/79956191/bridgebio-advances-cardiac-amyloidosis-management-with-the-drug